STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Tenax Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Tenax Therapeutics (NASDAQ: TENX) will present at two investor conferences in early December 2025: a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 at 4:15 p.m. ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 at 11:30 a.m. ET.

Participants include Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer. Live and archived webcasts will be available from the company’s investor relations webpage.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences:

8th Annual Evercore Healthcare Conference
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer
Date and Time: December 2, 2025, at 4:15 p.m. ET

Piper Sandler 37th Annual Healthcare Conference
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer
Date and Time: December 4, 2025, at 11:30 a.m. ET

The live and archived webcasts of the presentations will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Argot Partners
tenax@argotpartners.com


FAQ

When will Tenax Therapeutics (TENX) present at the Evercore Healthcare Conference?

Tenax will present a fireside chat on December 2, 2025 at 4:15 p.m. ET.

Who will represent Tenax Therapeutics (TENX) at the December 2025 investor conferences?

Presenters are Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer.

How can investors watch Tenax Therapeutics (TENX) presentations on December 2 and 4, 2025?

Live and archived webcasts will be accessible from the company’s investor relations webpage.

What format will Tenax Therapeutics (TENX) use at the Piper Sandler healthcare conference?

Tenax will participate in a fireside chat on December 4, 2025 at 11:30 a.m. ET.

Will Tenax Therapeutics (TENX) present new clinical data at the December 2025 conferences?

The announcement lists participants and times only and does not specify any new clinical data releases.

Where can I find the archived webcast for Tenax Therapeutics (TENX) conference presentations?

Archived webcasts will be posted on the company’s investor relations webpage after each presentation.
Tenax Therapeutics Inc

NASDAQ:TENX

TENX Rankings

TENX Latest News

TENX Latest SEC Filings

TENX Stock Data

50.89M
6.23M
0.21%
64.83%
6.53%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHAPEL HILL